Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress.
Karl-Heinz TomaszowskiSunetra RoyCarolina GuerreroPoojan ShuklaCaezaan KeshvaniYue ChenMartina OttXiaogang WuJianhua ZhangCourtney D D DiNardoDetlev SchindlerKatharina SchlacherPublished in: Nature communications (2023)
The prototypic cancer-predisposition disease Fanconi Anemia (FA) is identified by biallelic mutations in any one of twenty-three FANC genes. Puzzlingly, inactivation of one Fanc gene alone in mice fails to faithfully model the pleiotropic human disease without additional external stress. Here we find that FA patients frequently display FANC co-mutations. Combining exemplary homozygous hypomorphic Brca2/Fancd1 and Rad51c/Fanco mutations in mice phenocopies human FA with bone marrow failure, rapid death by cancer, cellular cancer-drug hypersensitivity and severe replication instability. These grave phenotypes contrast the unremarkable phenotypes seen in mice with single gene-function inactivation, revealing an unexpected synergism between Fanc mutations. Beyond FA, breast cancer-genome analysis confirms that polygenic FANC tumor-mutations correlate with lower survival, expanding our understanding of FANC genes beyond an epistatic FA-pathway. Collectively, the data establish a polygenic replication stress concept as a testable principle, whereby co-occurrence of a distinct second gene mutation amplifies and drives endogenous replication stress, genome instability and disease.
Keyphrases
- papillary thyroid
- genome wide
- bone marrow
- squamous cell
- endothelial cells
- chronic kidney disease
- high fat diet induced
- end stage renal disease
- wild type
- mesenchymal stem cells
- squamous cell carcinoma
- copy number
- genome wide identification
- magnetic resonance
- newly diagnosed
- dna repair
- type diabetes
- adipose tissue
- lymph node metastasis
- early onset
- gene expression
- computed tomography
- oxidative stress
- autism spectrum disorder
- insulin resistance
- young adults
- patient reported outcomes
- iron deficiency
- breast cancer risk